Microbion Corporation of Bozeman, MT, and Microbion Pharma Corp of Vancouver, BC (Microbion), a clinical-stage biopharmaceutical company, has received recommendation from the World Health Organization (WHO) for 'pravibismane' as the International Nonproprietary Name (INN) also commonly known as the generic name, for Microbion's lead broad-spectrum antimicrobial and antibiofilm agent, it was reported on Friday.

The announcement was made by Microbion.

The firm has completed Phase one and early Phase two trials of pravibismane formulated for topical and intrasurgical administration in diabetic foot ulcer infections and orthopaedic device-related infections, respectively. Microbion says that Pravibismane has broad spectrum, antibacterial efficacy against a broad range of pathogens, including multiple priority pathogens or 'superbugs' identified by the US Centers for Disease Control and Prevention (CDC). It has also demonstrated the ability to eradicate microbial biofilms.

;;;